Finerenone Cuts Kidney Failure Risk in Non-Diabetic
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients, reducing the combined risk of kidney failure, heart failure, or cardiovascular death by 23% in the FIND-CKD trial.
- The George Institute for Global Health led three international studies showing finerenone’s benefits extend to people with non-diabetic CKD and glomerular diseases, populations with few existing treatment options.
- FIND-CKD trial results, published in The New England Journal of Medicine, involved 1,584 patients across 24 countries and demonstrated consistent kidney and cardiovascular protection with finerenone plus standard care.
- Researchers observed reduced risks of kidney failure, cardiovascular death, and overall mortality, with benefits seen across diabetic and non-diabetic forms of kidney disease, suggesting a broader therapeutic role.
Why it matters: Millions with non-diabetic kidney disease—who currently lack effective treatments—could now benefit from finerenone, shifting clinical guidelines and expanding the drug’s use far beyond its approved diabetes-linked indication.
